Following the same trend, the bispecific antibody ATOR-1015 is also a new generation of bispecific anti-CTLA-4 (IgG1), designed to target the high co-expression of CTLA-4 and OX40 on tumor-infiltrating Tregs. Here, TNFRSF4 is linked to neoplasm.